These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9333147)

  • 21. [Hydroxyurea and HIV infection].
    Nkoghe D; Kola L; Léonard P; Demonty J; Moutschen M
    Rev Med Liege; 2000 Jul; 55(7):721-4. PubMed ID: 11014107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinically relevant genotype interpretation of resistance to didanosine.
    Marcelin AG; Flandre P; Pavie J; Schmidely N; Wirden M; Lada O; Chiche D; Molina JM; Calvez V;
    Antimicrob Agents Chemother; 2005 May; 49(5):1739-44. PubMed ID: 15855490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
    J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine.
    Luzzati R; Di Perri G; Fendt D; Ramarli D; Broccali G; Concia E
    J Antimicrob Chemother; 1998 Oct; 42(4):565-6. PubMed ID: 9818769
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
    Mayhew CN; Sumpter R; Inayat M; Cibull M; Phillips JD; Elford HL; Gallicchio VS
    Antiviral Res; 2005 Jan; 65(1):13-22. PubMed ID: 15652967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine.
    Frenkel LM; Wagner LE; Atwood SM; Cummins TJ; Dewhurst S
    J Clin Microbiol; 1995 Feb; 33(2):342-7. PubMed ID: 7714190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
    Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.
    Vila J; Nugier F; Barguès G; Vallet T; Peyramond D; Hamedi-Sangsari F; Seigneurin JM
    Lancet; 1997 Aug; 350(9078):635-6. PubMed ID: 9288048
    [No Abstract]   [Full Text] [Related]  

  • 29. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
    Montaner JS; Mo T; Raboud JM; Rae S; Alexander CS; Zala C; Rouleau D; Harrigan PR
    J Infect Dis; 2000 Feb; 181(2):729-32. PubMed ID: 10669364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea.
    Nokta M; Rossero R; Loesch K; Pollard RB
    AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1633-8. PubMed ID: 9430255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
    Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
    J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea for HIV infection.
    Zachary KC; Davis B
    AIDS Clin Care; 1998 Apr; 10(4):25-6, 32. PubMed ID: 11365149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.
    Capdepont S; Aurillac-Lavignolle V; Faure M; Dupon M; Morlat P; Ragnaud JM; Chêne G; Fleury H; Masquelier B;
    J Clin Virol; 2006 May; 36(1):36-42. PubMed ID: 16513416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
    Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of hydroxyurea in heavily pretreated patients with HIV infection.
    Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N
    Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection.
    Simonelli C; Comar M; Zanussi S; De Paoli P; Tirelli U; Giacca M
    AIDS; 1997 Aug; 11(10):1299-300. PubMed ID: 9256953
    [No Abstract]   [Full Text] [Related]  

  • 37. Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
    AIDS Treat News; 1999 Dec; (No 332):8. PubMed ID: 11367131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds.
    Bagnarelli P; Menzo S; Valenza A; Paolucci S; Petroni S; Scalise G; Sampaolesi R; Manzin A; Varaldo PE; Clementi M
    J Clin Microbiol; 1995 Jan; 33(1):16-23. PubMed ID: 7699034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New data intensifies interest in hydroxyurea.
    Santiago LG
    GMHC Treat Issues; 1995 Sep; 9(9):1, 3-4. PubMed ID: 11362902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.